Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Apr 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called SBRT, or stereotactic body radiotherapy, which delivers a high dose of radiation to specific areas in the chest to treat different types of thoracic cancers, such as lung cancer. The trial aims to understand how safe and effective SBRT is when targeting tumors in various locations within the chest, as different areas may respond differently to radiation. Participants will receive tailored doses of radiation based on the exact location of their tumor, and the main goals are to see how well the treatment controls the cancer and to monitor any side effects.

To be eligible for this trial, participants should have a diagnosed malignant tumor that meets certain size and location criteria, and they should not have widespread cancer metastasis, meaning the cancer has not spread extensively to other parts of the body. Other factors, like overall health and the ability to tolerate treatment, are also considered. Those who join the trial can expect to receive a precise treatment plan and will be closely monitored throughout the process. It’s important to note that the trial is currently recruiting participants aged 65 to 74 years and is open to both men and women.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathological diagnosis was malignant tumor.
• • The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm.
• • There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.
• • KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.
• Exclusion Criteria:
• • Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.
• • The general condition is poor, and the expected survival time is less than 3 months.
• • Psychiatric patients or poor compliance, unable to cooperate to complete treatment.
• • For other reasons, the researcher believes that it is not suitable to participate in this trial.